Technology | May 07, 2014

FDA Clears GE’s Discovery IGS 740 Mobile Angiography System

System designed to meet needs of interventional radiology without limits of fixed-base systems

GE Healthcare Discovery IGS 740 Mobile Angiography System FDA Approval

FDA Clears GEs Discovery IGS 740 Mobile Angiography System


May 7, 2014 — GE Healthcare received U.S. Food and Drug Administration (FDA) clearance for its Discovery IGS 740, a new rail-free mobile angiography system with a 41x41 cm detector. The Discovery IGS 740 is the first of this kind of mobile angiography system in the industry to receive FDA approval.

This new imaging system puts interventional radiologists at the center of their procedures. The rail-free design allows healthcare professionals ample access to the patient while freeing clinical teams from the constraints of fixed ceiling-mounted system rails. Its wide bore C-arm and dedicated arm-imaging positions create ease in imaging the anatomy of interest and full patient access from the left or right. A rotating laser continuously scans the room so the system knows where it is at all times.

By eliminating the ceiling rails, installation is simplified for flexibility in designing the room and positioning ceiling-mounted ancillaries (monitors, radshields, lights) where healthcare professionals need them.

The Discovery IGS 740 is equipped with two customizable parking positions to accommodate multiple room sizes and shapes. The 41x41-cm detector enables imaging of large organs, such as the liver and simultaneous coverage of both legs. The wide-bore C-arm helps interventional radiologists image large patients and conveniently perform off centered 3-D acquisitions. In addition, the system comes equipped with more than 20 advanced applications, such as FlightPlan for Liver, which helps clinicians identify tumor-feeding vessels in a few clicks, and be selective during liver embolizations.

For more information: newsroom.gehealthcare.com


Related Content

Feature | Cath Lab | Kyle Hardner

Since receiving FDA approval in 2016, intravascular lithotripsy (IVL) systems have grown in popularity among ...

Home November 14, 2025
Home
News | Cath Lab

Nov. 11, 2025 — FastWave Medical has successfully completed enrollment in its 30-patient coronary feasibility study and ...

Home November 13, 2025
Home
News | Cath Lab

Oct. 28, 2025 — Results from the first-of-its-kind randomized PROCTOR trial found that a strategy of saphenous vein ...

Home November 04, 2025
Home
News | Cath Lab

Oct. 27, 2025 — Results from the PREVUE-VALVE study suggest that there are currently at least 4.7 million people aged 65 ...

Home October 29, 2025
Home
News | Cath Lab

Oct. 25, 2025 — Medtronic plc has announced the launch of the Stedi Extra Support guidewire, designed to enhance ...

Home October 28, 2025
Home
News | Cath Lab

Oct. 27, 2025 — Elixir Medical, a developer of technologies to treat cardiovascular disease, has announced new clinical ...

Home October 28, 2025
Home
News | Cath Lab

Oct. 22, 2025 — Heartflow, Inc. has introduced Heartflow PCI Navigator, the newest addition to the Heartflow One ...

Home October 23, 2025
Home
News | Cath Lab

Oct. 15, 2025 — Stereotaxis recently announced it has obtained CE Mark in Europe and submitted a 510(k) application to ...

Home October 16, 2025
Home
News | Cath Lab

Oct. 7, 2025 — Medtronic has announced the full distribution of the Neuroguard IEP System (Neuroguard) after a ...

Home October 07, 2025
Home
News | Cath Lab

Sept. 22, 2025 — Nicklaus Children's Heart Institute in Miami, Florida, is now offering bedside transcatheter patent ...

Home September 23, 2025
Home
Subscribe Now